Construction and validation of a novel ten miRNA-pair based signature for the prognosis of clear cell renal cell carcinoma

被引:0
|
作者
Wang, Yulin [1 ,2 ,3 ]
Shen, Ziyan [1 ,2 ,4 ]
Mo, Shaocong [5 ]
Dai, Leijie [6 ]
Song, Biao [7 ]
Gu, Wenchao [8 ]
Ding, Xiaoqiang [1 ,2 ,3 ,4 ]
Zhang, Xiaoyan [1 ,2 ,3 ,4 ,9 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Nephrol, 180 Fenglin Rd, Shanghai 200032, Peoples R China
[2] Shanghai Med Ctr Kidney Dis, Shanghai 200032, Peoples R China
[3] Shanghai Key Lab Kidney & Blood Purificat, Shanghai 200032, Peoples R China
[4] Shanghai Inst Kidney & Dialysis, 136 Med Coll Rd, Shanghai 200032, Peoples R China
[5] Fudan Univ, Huashan Hosp, Dept Digest Dis, Shanghai 200040, Peoples R China
[6] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai 200032, Peoples R China
[7] Peking Union Med Coll Hosp, Dept Dermatol, Beijing 100005, Peoples R China
[8] Gunma Univ, Dept Diagnost Radiol & Nucl Med, Grad Sch Med, Maebashi 3718511, Japan
[9] Shanghai Inst Kidney & Dialysis, 136 Med Coll Rd, Shanghai 200032, Peoples R China
来源
TRANSLATIONAL ONCOLOGY | 2022年 / 25卷
关键词
miRNA-pair; ccRCC; Prognosis; Signature; Immune; Bioinformatics; CANCER; EXPRESSION; METASTASIS; MODELS; IDENTIFICATION; ENCYCLOPEDIA; MICRORNAS; DISCOVERY; CELLMINER; NOMOGRAM;
D O I
10.1016/j.tranon.2022.101519
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Clear cell renal cell carcinoma (ccRCC) is the most predominate pathological subtype of renal cell carcinoma, causing a recurrence or metastasis rate as high as 20% to 40% after operation, for which effective prognostic signature is urgently needed. Methods: The mRNA and miRNA profiles of ccRCC specimens were collected from the Cancer Genome Atlas. MiRNA-pair risk score (miPRS) for each miRNA pair was generated as a signature and validated by univariate and multivariate Cox proportional hazards regression analysis. Functional enrichment was performed, and im-mune cells infiltration, as well as tumor mutation burden (TMB), and immunophenoscore (IPS) were evaluated between high and low miPRS groups. Target gene-prediction and differentially expressed gene-analysis were performed based on databases of miRDB, miRTarBase, and TargetScan. Multivariate Cox proportional hazards regression analysis was adopted to establish the prognostic model and Kaplan-Meier survival analysis was performed. Findings: A novel 10 miRNA-pair based signature was established. Area under the time-dependent receiver operating curve proved the performance of the signature in the training, validation, and testing cohorts. Higher TMB, as well as the higher CTLA4-negative PD1-negative IPS, were discovered in high miPRS patients. A prognostic model was built based on miPRS (1 year-, 5 year-, 10 year-ROC-AUC=0.92, 0.84, 0.82, respectively). Interpretation: The model based on miPRS is a novel and valid tool for predicting the prognosis of ccRCC. Funding: This study was supported by research grants from the China National Natural Scientific Foundation (81903972, 82002018, and 82170752) and Shanghai Sailing Program (19YF1406700 and 20YF1406000).
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Systematic Analysis of Immune Infiltration and Predicting Prognosis in Clear Cell Renal Cell Carcinoma Based on the Inflammation Signature
    Zhang, Yuke
    Shi, Chunliu
    Chen, Yue
    Wang, Hongwei
    Chen, Feng
    Han, Ping
    GENES, 2022, 13 (10)
  • [42] Construction of a Novel Multigene Panel Potently Predicting Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma
    Lin, Xiaozeng
    Kapoor, Anil
    Gu, Yan
    Chow, Mathilda Jing
    Peng, Jingyi
    Major, Pierre
    Tang, Damu
    CANCERS, 2020, 12 (11) : 1 - 19
  • [43] A Novel Pyroptosis-Related Prognostic Signature for Risk Stratification and Clinical Prognosis in Clear Cell Renal Cell Carcinoma
    Pan, Xiao-qiong
    Huang, Wen
    Jin, Ling-wei
    Lin, Hua-zhen
    Xu, Xiao-yan
    DISEASE MARKERS, 2022, 2022
  • [44] The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma
    Zhang, Lishuo
    Di, Longjiang
    Liu, Jinhui
    Lei, Xianli
    Gu, Maoli
    Zhang, Wenjing
    Wang, Yufu
    FRONTIERS IN GENETICS, 2023, 14
  • [45] Novel amino acid metabolism-related gene signature to predict prognosis in clear cell renal cell carcinoma
    Cheng, Xiaofeng
    Deng, Wen
    Zhang, Zhicheng
    Zeng, Zhenhao
    Liu, Yifu
    Zhou, Xiaochen
    Zhang, Cheng
    Wang, Gongxian
    FRONTIERS IN GENETICS, 2022, 13
  • [46] Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma
    Lebdai, Souhil
    Verhoest, Gregory
    Parikh, Hemang
    Jacquet, Solene Florence
    Bensalah, Karim
    Chautard, Denis
    Leclercq, Nathalie Rioux
    Azzouzi, Abdel Rahmene
    Bigot, Pierre
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (02) : 69.e11 - 69.e18
  • [47] Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma
    Zhou, Libin
    Fang, Hualong
    Guo, Fei
    Yin, Min
    Long, Huimin
    Weng, Guobin
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (08)
  • [48] Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma
    Wang, Yi
    Cong, Rong
    Liu, Shouyong
    Zhu, Bingye
    Wang, Xing
    Xing, Qianwei
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [49] Identification of a 4-microRNA Signature for Clear Cell Renal Cell Carcinoma Metastasis and Prognosis
    Wu, Xiwei
    Weng, Lihong
    Li, Xuejun
    Guo, Chao
    Pal, Sumanta K.
    Jin, Jennifer M.
    Li, Yuping
    Nelson, Rebecca A.
    Mu, Bing
    Onami, Susan H.
    Wu, Jeffrey J.
    Ruel, Nora H.
    Wilczynski, Sharon P.
    Gao, Hanlin
    Covarrubias, Maricela
    Figlin, Robert A.
    Weiss, Lawrence M.
    Wu, Huiqing
    PLOS ONE, 2012, 7 (05):
  • [50] A Metastasis-Related lncRNA Signature Correlates With the Prognosis in Clear Cell Renal Cell Carcinoma
    Dou, Qian
    Gao, Shun
    Gan, Hua
    Kang, Zhao
    Zhang, Han
    Yang, Yichun
    Tong, Hang
    FRONTIERS IN ONCOLOGY, 2021, 11